Movement Alert｜Neurocrine Biosciences Rises 5.85% in Regular Trading, RBC Raises Target Price on Crenessity Commercial Outlook

Market Focus06-04

On June 4, Neurocrine Biosciences rose 5.85% in regular trading, trading at $163.94/share, with trading volume of $89.26 million.

On the news front, RBC Capital Markets recently raised its target price on the company from $180 to $183, maintaining an Outperform rating, citing further upside potential in Crenessity's commercial growth trajectory.

RBC conducted a survey of 35 endocrinologists, which revealed that physicians currently use Crenessity in approximately 23% of relevant patients, with expectations to increase adoption to 37% by year-end. Based on these findings, RBC raised its full-year Crenessity sales estimate from $734 million to $750 million, significantly above the Street consensus of approximately $650 million. The firm noted that this target remains achievable even under more conservative growth assumptions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1109929363?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 00:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109929363","market":"us","top_or_hot":-1,"title":"Movement Alert｜Neurocrine Biosciences Rises 5.85% in Regular Trading, RBC Raises Target Price on Crenessity Commercial Outlook","media":"Market Focus","content":"<p><p>On June 4, Neurocrine Biosciences rose 5.85% in regular trading, trading at $163.94/share, with trading volume of $89.26 million.</p><p>On the news front, RBC Capital Markets recently raised its target price on the company from $180 to $183, maintaining an Outperform rating, citing further upside potential in Crenessity's commercial growth trajectory.</p><p>RBC conducted a survey of 35 endocrinologists, which revealed that physicians currently use Crenessity in approximately 23% of relevant patients, with expectations to increase adoption to 37% by year-end. Based on these findings, RBC raised its full-year Crenessity sales estimate from $734 million to $750 million, significantly above the Street consensus of approximately $650 million. The firm noted that this target remains achievable even under more conservative growth assumptions.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Neurocrine Biosciences Rises 5.85% in Regular Trading, RBC Raises Target Price on Crenessity Commercial Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Neurocrine Biosciences Rises 5.85% in Regular Trading, RBC Raises Target Price on Crenessity Commercial Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-04 00:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 4, Neurocrine Biosciences rose 5.85% in regular trading, trading at $163.94/share, with trading volume of $89.26 million.</p><p>On the news front, RBC Capital Markets recently raised its target price on the company from $180 to $183, maintaining an Outperform rating, citing further upside potential in Crenessity's commercial growth trajectory.</p><p>RBC conducted a survey of 35 endocrinologists, which revealed that physicians currently use Crenessity in approximately 23% of relevant patients, with expectations to increase adoption to 37% by year-end. Based on these findings, RBC raised its full-year Crenessity sales estimate from $734 million to $750 million, significantly above the Street consensus of approximately $650 million. The firm noted that this target remains achievable even under more conservative growth assumptions.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NBIX","symbol_name":"神经分泌生物科学","start_time":0,"source_url":"","article_id":"1109929363","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109929363","pubTimestamp":1780503428,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 4, Neurocrine Biosciences rose 5.85% in regular trading, trading at $163.94/share, with trading volume of $89.26 million.On the news front, RBC Capital Markets recently raised its target...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NBIX":"神经分泌生物科学"},"translate_title":"动向提示|Neurocrine Biosciences常规交易涨5.85%加拿大皇家银行因Crenessity商业前景上调目标价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":1},"content_text":"On June 4, Neurocrine Biosciences rose 5.85% in regular trading, trading at $163.94/share, with trading volume of $89.26 million.On the news front, RBC Capital Markets recently raised its target price on the company from $180 to $183, maintaining an Outperform rating, citing further upside potential in Crenessity's commercial growth trajectory.RBC conducted a survey of 35 endocrinologists, which revealed that physicians currently use Crenessity in approximately 23% of relevant patients, with expectations to increase adoption to 37% by year-end. Based on these findings, RBC raised its full-year Crenessity sales estimate from $734 million to $750 million, significantly above the Street consensus of approximately $650 million. The firm noted that this target remains achievable even under more conservative growth assumptions.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109929363","isCrawlerRequest":true}